Search

Relatlimab

[L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia

Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

Daprodustat

[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis.

Oxymetazoline

[L15062] As an effective decongestant, oxymetazoline is available in over-the-counter intranasal sprays used to relieve nasal and sinus congestion caused by a wide variety of conditions, such as common … [L15057] In July 2020, the FDA approved the use of an ophthalmic formulation of oxymetazoline (Upneeq) in adults with acquired blepharoptosis, or ptosis, making it the first FDA-approved medical treatment

Etuvetidigene Autotemcel

Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]

Mobocertinib

[A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations … as compared to "classical" _EGFR_ mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors.

Isosulfan blue

Caplacizumab

Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]

Tecovirimat

[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.

Amivantamab

[A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … [L41469] On December 17, 2025, the U.S.